Breaking News

Tweet TWEET

Enzo Biochem Reports Jury Declares Life Technologies Infringed Company Patents and Awards Enzo $48.6 Million

  Enzo Biochem Reports Jury Declares Life Technologies Infringed Company
  Patents and Awards Enzo $48.6 Million

                Court to Decide Additional Pre-Judgment Award

Business Wire

NEW YORK -- November 02, 2012

Enzo Biochem Inc. (NYSE:ENZ) reported yesterday that the jury in the Enzo
action entitled Enzo Biochem, Inc. et al. vs. Applera Corp. and Tropix Inc. in
New Haven, CT Civil Action No. 3:04cv929 (JBA), has rendered its verdict that
Applera Corp., now Life Technologies, Inc. (NASDAQ:LIFE), infringed Enzo’s
patents covering pioneering technologies relating to compounds used in DNA
sequencing systems to read the genetic code. The jury awarded $48.6 million in
direct infringement penalties. In addition, a pre-judgment (interest) award
will be awarded by the Court. Attorneys for Enzo estimate that the addition of
the pre-judgment award should add additional recoveries of up to tens of
millions of dollars. The jury also found that Life Technologies’ sequencing
instruments induced its customers to infringe Enzo’s patent No. 5,449,767. The
sales of such instruments are estimated to be $770 million. Enzo plans to seek
damages based on the jury decision that the sale of Life Technologies’
sequencing instruments induced infringement of Enzo patents. Yale University
was also a plaintiff.

Enzo expects that today’s decision will have a positive impact on the
resolution of pending actions that Enzo brought in the U.S. Southern District
Court in New York City, which involve additional defendants, patents and
contract issues. Defendants in those suits include Amersham PLC, Amersham
Biosciences, Roche Diagnostics, PerkinElmer, Inc., PerkinElmer Life Sciences,
Inc, Molecular Probes, Inc.(now owned by Life Technologies), Orchid Cellmark,
Inc. (now owned by Laboratory Corporation of America) and Affymetrix, Inc.

“We are obviously very gratified and pleased with the jury’s decision,” said
Elazar Rabbani, Ph.D., Chairman and CEO of Enzo. “The technologies subject to
the litigation helped pave the way for major developments in important areas
in biological science and medicine. The case has taken eight years, but we
have finally prevailed. It is a vindication of the investments we have made in
developing and protecting our intellectual property.”

The trial resulted from a lawsuit initially filed by Enzo in June 2004, in the
United States District Court for the District of Connecticut against Applera
Corporation and its subsidiary Tropix Inc. charging them not only with patent
infringement, but also with providing others with unauthorized and prohibited
access to the patented products and technologies.

The inventions described in the patents cover compositions and methods for
detecting and reading genetic materials. The applications for these inventions
are diverse, ranging from detecting pathogens and human diseases, such as
cancer, to decoding and analyzing the human genome.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of
clinical laboratories, life sciences and therapeutics through the development
of unique diagnostic platform technologies that provide numerous advantages
over previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products systems and services
that meet the ever-changing and rapidly growing needs of health care both
today and into the future. Underpinning Enzo Biochem’s products and
technologies is a broad and deep intellectual property portfolio, with patent
coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release
may be considered "forward-looking" statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements include
declarations regarding the intent, belief or current expectations of the
Company and its management, including those related to cash flow, gross
margins, revenues, and expenses are dependent on a number of factors outside
of the control of the company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other expenses,
government regulations, litigations, and general business conditions. See Risk
Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2012.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The Company
disclaims any obligations to update any forward-looking statement as a result
of developments occurring after the date of this press release.

Contact:

For Enzo Biochem, Inc.
Anreder & Company
Steven Anreder, 212-532-3232
steven.anreder@anreder.com
or
CEOcast, Inc.
Michael Wachs, 212-732-4300
mwachs@ceocast.com